FVIII regulates the molecular profile of endothelial cells: functional impact on the blood barrier and macrophage behavior

• Published in: Cellular and molecular life sciences : CMLS 2022-03, Vol.79 (3), p.145-145, Article 145
• Main Authors: Cadé, Marie, Muñoz-Garcia, Javier, Babuty, Antoine, Paré, Louis, Cochonneau, Denis, Fekir, Karim, Chatelais, Mathias, Heymann, Marie-Françoise, Lokajczyk, Anna, Boisson-Vidal, Catherine, Heymann, Dominique
• Format: Article
• Language: English
• Subjects: Adhesion; Biochemistry; Biomedical and Life Sciences; Biomedical materials; Biomedicine; Bleeding; Blood coagulation; Cell Adhesion; Cell Biology; Cell Membrane Permeability; Cell Movement; Cellular Biology; Coagulation factor VIII; Coagulation factors; Endothelial cells; Endothelium; Endothelium, Vascular - cytology; Endothelium, Vascular - metabolism; Extracellular matrix; Factor VIII - genetics; Factor VIII - metabolism; Fragility; Hematology; Hemophilia; Hereditary diseases; Human health and pathology; Humans; Immune system; Leukocyte migration; Leukocytes; Life Sciences; Macrophages; Macrophages - cytology; Macrophages - metabolism; Monocytes; Neovascularization, Physiologic; Original; Original Article; Osteopenia; Permeability; Physiological effects; Proteome; Thrombin; Transcriptome; Transcriptomics; Tubes
• ISSN: 1420-682X; 1420-9071
• DOI: 10.1007/s00018-022-04178-5

Hemophilia A is an inherited X-linked recessive bleeding disorder caused by deficient activity of blood coagulation factor VIII (FVIII). In addition, hemophilia patients show associated diseases including osteopenia, altered inflammation and vascular fragility which may represent the consequence of recurrent bleeding or may be related to the direct FVIII deficiency. Nowadays, recombinant FVIII is proposed to treat hemophilia patients with no circulating FVIII inhibitor. Initially described as a coenzyme to factor IXa for initiating thrombin generation, there is emerging evidence that FVIII is involved in multiple biological systems, including bone, vascular and immune systems. The present study investigated: (i) the functional activities of recombinant human FVIII (rFVIII) on endothelial cells, and (ii) the impact of rFVIII activities on the functional interactions of human monocytes and endothelial cells. We then investigated whether rFVIII had a direct effect on the adhesion of monocytes to the endothelium under physiological flow conditions. We observed that direct biological activities for rFVIII in endothelial cells were characterized by: (i) a decrease in endothelial cell adhesion to the underlying extracellular matrix; (ii) regulation of the transcriptomic and protein profiles of endothelial cells; (iii) an increase in the vascular tubes formed and vascular permeability in vitro; and (iv) an increase in monocyte adhesion activated endothelium and transendothelial migration. By regulating vascular permeability plus leukocyte adhesion and transendothelial migration, the present work highlights new biological functions for FVIII.